People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aptinyx Inc. | — | Pharmaceuticals | Series C | $95.0M | $2.5B | 2017 |
Adam M. Koppel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adam M. Koppel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick G. Enright | 1 | 7 |
| James N. Topper | 1 | 5 |
| Norbert G. Riedel | 1 | 3 |
| Wilbur H. Gantz III | 1 | 3 |
| Ashish G. Khanna | 1 | 2 |
| Ashish M. Khanna | 1 | 2 |
| Joseph R. Moskal | 1 | 2 |
| Terry P. Gould | 1 | 2 |
| Patrick H. Enright | 1 | 1 |
| Torsten M. Madsen | 1 | 1 |
| Liam P. Ratcliffe | 1 | 1 |
| Andrew D. Kidd | 1 | 1 |
| James P. Topper | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.